Trametinib Dimethyl Sulfoxide

5 trials 1 recruiting LOncology Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

4 Completed trials

2 Sponsors

12 Countries

Phase II

Phase I/II

Phase IV

Phase I (Other)

Phase II: 2 Phase I/II: 1 Phase IV: 1 Phase I (Other): 1

Oversight events:

8 temporary halts across 2 trials

View oversight register →

Indications tested

Colorectal cancer 1 Metastatic malignant melanoma 1 Rosai-Dorfman syndrome 1 Langerhans' cell histiocytosis 1 Langerhans cell sarcoma 1 Non-small cell lung cancer 1 Erdheim-Chester disease 1 Neoplasm malignant 1

Sponsors using this IMP

Novartis Pharma AG 4 Instytut Matki I Dziecka 1

All trials

5 total

Platform study of JDQ443 in combinations in patients with advanced solid tumors harboring the KRAS G12C mutation Recruiting

2023-506716-41-00 Phase I/II 5 countries Novartis Pharma AG
Study of efficacy and safety of LXH254 combinations in patients with previously treated unresectable or metastatic melanoma Ended

2024-511934-11-00 Phase II 4 countries Novartis Pharma AG
To test the safety, efficacy and tolerability of a drug called trametinib and determine the duration of treatment in children with histiocyt… Ended

2024-515896-37-00 Phase II 1 country Instytut Matki I Dziecka
Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatme… Ended

2023-508841-42-00 Phase I (Other) 8 countries Novartis Pharma AG
This study will facilitate data collection of the long-term outcomes of pediatric subjects who have been treated in clinical trials with dab… Ended

2023-509276-42-00 Phase IV 10 countries Novartis Pharma AG

Showing 1–5 of 5 trials

← All drugs A–Z